<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02518620</url>
  </required_header>
  <id_info>
    <org_study_id>ALX0061-C203</org_study_id>
    <secondary_id>2014-003034-42</secondary_id>
    <nct_id>NCT02518620</nct_id>
  </id_info>
  <brief_title>An Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of ALX-0061 in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects With Moderate to Severe Rheumatoid Arthritis Who Have Completed One of the Preceding Phase IIb Studies With ALX-0061</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ablynx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ablynx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a multicenter, open-label extension (OLE) Phase II study designed to evaluate the
      long-term efficacy and safety of ALX-0061 (i.e., vobarilizumab) administered subcutaneously
      (s.c.) in subjects with active rheumatoid arthritis (RA) who had completed the treatment and
      assessment period of one of the preceding Phase IIb studies with ALX-0061 (ALX0061-C201 and
      ALX0061-C202; placebo and ALX-0061 treatment arms only), and who achieved at least 20%
      improvement in swollen joint count (SJC) and/or tender joint count (TJC) (66/68 counts)
      compared to Baseline at the final visit of the preceding study (i.e., Week 24 for Study
      ALX0061-C201 and Week 12 for Study ALX0061-C202).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible subjects received one of the following treatments during the preceding Phase IIb
      studies ALX0061-C201 and ALX0061-C202:

        -  Study ALX0061-C201:

             -  Placebo (+ methotrexate [MTX]), or

             -  ALX-0061 75 mg every 4 weeks (q4w) (+ MTX), or

             -  ALX-0061 150 mg q4w (+ MTX), or

             -  ALX-0061 150 mg every 2 weeks (q2w) (+ MTX), or

             -  ALX-0061 225 mg q2w (+ MTX), for 24 weeks

        -  Study ALX0061-C202:

             -  ALX-0061 150 mg q4w, or

             -  ALX-0061 150 mg q2w, or

             -  ALX-0061 225 mg q2w, for 12 weeks

      At the Week 24 (ALX0061-C201) or Week 12 (ALX0061-C202) visit of the previous study, informed
      consent was obtained from all subjects who were deemed potentially eligible for the OLE
      study, according to the inclusion and exclusion criteria. This was marked as the Week 0 visit
      of the C203 study. Of note, the Baseline time point in the analyses of this study was defined
      the Baseline value of the parent study.

      In this OLE study, eligible subjects received ALX-0061 150 mg s.c. injections, beginning at
      Week 0 and every 2 weeks thereafter, up to and including Week 102. Eligible subjects from the
      preceding study ALX0061-C201 also continued their MTX treatment.

      Maintenance of the response (i.e., at least 20% improvement in both SJC and TJC compared to
      Baseline of the preceding study) was reassessed at the study visits at Weeks 12, 24, 36, 48,
      60, 72, 84, and 96. Subjects who failed to maintain response and met the Efficacy
      Discontinuation Criteria were discontinued from this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Actual">August 2018</completion_date>
  <primary_completion_date type="Actual">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and Percentage of Subjects With American College of Rheumatology (ACR) 20 Response.</measure>
    <time_frame>At Weeks 0, 12, 48, and 104</time_frame>
    <description>ACR 20 response is defined as:
20% improvement in tender joint count (TJC; 68 joints) relative to Week 0 AND
20% improvement in swollen joint count (SJC; 66 joints) relative to Week 0 AND
20% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - visual analogue scale [VAS])
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI)
C-reactive protein (CRP) level
ACR20 responses were measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Percentage of Subjects With ACR50 Response.</measure>
    <time_frame>At Weeks 0, 12, 48, and 104</time_frame>
    <description>ACR50 response is defined as:
50% improvement in TJC (68 joints) relative to Week 0 AND
50% improvement in SJC (66 joints) relative to Week 0 AND
50% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - VAS)
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by HAQ-DI
CRP level
ACR50 responses were measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Percentage of Subjects With ACR70 Response.</measure>
    <time_frame>At Weeks 0, 12, 48, and 104</time_frame>
    <description>ACR70 response is defined as:
70% improvement in TJC (68 joints) relative to Week 0 AND
70% improvement in SJC (66 joints) relative to Week 0 AND
70% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - VAS)
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by HAQ-DI
CRP level
ACR70 responses were measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ACR-N Index of Improvement</measure>
    <time_frame>At Weeks 0, 12, 48, and 104</time_frame>
    <description>The ACR-N Index of Improvement is defined as the minimum of the following 3 criteria:
The percent improvement from Week 0 in TJCs
The percent improvement from Week 0 in SJCs
The median percent improvement from Week 0 for the following 5 assessments:
Subject's assessment of pain (VAS)
Subject's global assessment of disease activity (VASPHA)
Physician's global assessment of disease activity (VASPHA)
Subject's assessment of physical function as measured by the HAQ-DI
CRP level
ACR-N Index of Improvement was measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Percentage of Subjects in Remission or With Low, Moderate or High Disease Activity Based on Disease Activity Score Using 28 Joint Counts (DAS28) Using Estimated Sedimentation Rate (ESR)</measure>
    <time_frame>At Weeks 0, 12, 48, and 104</time_frame>
    <description>DAS28(ESR) = (0.56 × √TJC28) + (0.28 × √SJC28) + (0.70 × ln[ESR]) +(0.014 × VASPA)
Remission = DAS28(ESR) &lt; 2.6
Low disease activity = 2.6 ≤ DAS28 ≤ 3.2
Moderate disease activity = 3.2 &lt; DAS28 ≤ 5.1
High disease activity = DAS28 &gt; 5.1
Disease activity based on DAS28(ESR) was measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Percentage of Subjects With DAS28 Using C-reactive Protein (CRP) &lt; 2.6, Low, Moderate or High Disease Activity Based on DAS28(CRP)</measure>
    <time_frame>At Weeks 0, 12, 48, and 104</time_frame>
    <description>DAS28(CRP) = (0.56 × √TJC28) + (0.28 × √SJC28) + (0.36 × ln[CRP+1]) + (0.014 × VASPA) + 0.96
DAS28(CRP) &lt; 2.6
Low disease activity = 2.6 ≤ DAS28 ≤ 3.2
Moderate disease activity = 3.2 &lt; DAS28 ≤ 5.1
High disease activity = DAS28 &gt; 5.1
Disease activity based on DAS28(CRP) was measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">406</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>ALX-0061 150 mg q2w (+ MTX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALX-0061</intervention_name>
    <description>Subjects received ALX-0061 150 mg s.c. injections, beginning at Week 0 and q2w thereafter, up to and including Week 102. Subjects from the preceding study ALX0061-C201 also continued their MTX treatment.</description>
    <arm_group_label>ALX-0061 150 mg q2w (+ MTX)</arm_group_label>
    <other_name>Vobarilizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have been eligible for one of the preceding Phase IIb studies with ALX-0061
             (study ALX0061-C201 or ALX0061-C202), have been randomized to placebo or one of the
             ALX-0061 arms (subjects randomized to tocilizumab [TCZ] in study ALX0061-C202 were not
             eligible), and completed the entire treatment and assessment period of the preceding
             studies (i.e., 24 weeks for study ALX0061-C201 and 12 weeks for study ALX0061-C202).

          -  Must have reached at least 20% improvement in SJC and/or TJC (66/68 counts) compared
             to Week 0 at Week 24 for subjects participating in the preceding Phase IIb ALX0061
             C201 study, or at Week 12 for subjects participating in the preceding Phase IIb
             ALX0061-C202 study

          -  Female subjects of childbearing potential (excluding postmenopausal women, sterilized,
             ovariectomized, and hysterectomized women) must agree to use 2 generally accepted
             adequate contraceptive methods of which 1 is a barrier method (e.g., hormonal
             contraception stabilized for at least 1 month [oral, patch, depot, injectable, vaginal
             ring] in combination with condom by partner) or should agree upon continuous
             abstinence from heterosexual contact from screening/baseline until at least 6 months
             after last dosing. Male subjects must use condoms for the duration of the study and
             for at least 6 months after last administration of study drug.

          -  Ability to comprehend and willingness to sign the informed consent form (ICF).

          -  An understanding of and ability and willingness to adhere to the study visit schedule
             and other protocol requirements.

        Exclusion Criteria:

          -  Received TCZ during the previous Study ALX0061-C202.

          -  Received any prohibited treatment during the previous Phase IIb studies (ALX0061-C201
             or ALX0061-C202.

          -  Diagnosis of or suspicion of a serious infection (requiring parental antibiotics
             and/or hospitalization) or tuberculosis during the preceding study.

          -  Diagnosis of malignancy or demyelinating disease during the preceding study.

          -  Any active or recurrent viral infection that made the subject unsuitable for the study
             based on the Investigator's clinical assessment, including recurrent/disseminated
             herpes zoster.

          -  Diagnosis of congestive heart failure class III or IV (as defined by the New York
             Heart Association), unstable angina pectoris, myocardial infarction, and/or
             cerebrovascular accident during the preceding study.

          -  Abnormality in laboratory test results observed at the Week 22 visit for subjects
             participating in the preceding Phase IIb ALX0061-C201 study, or observed at the Week
             10 visit for subjects participating in the preceding Phase IIb ALX0061-C202 study:

               1. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels ≥ 2
                  times the upper limit of normal (ULN).

               2. Hemoglobin levels ≤ 85 g/L (8.5 g/dL).

               3. Platelet count ≤ 75 x 109/L (75,000 cells/mm³).

               4. Absolute neutrophil count &lt; 1.5 x 109/L.

               5. Serum creatinine levels ≥ 1.5 mg/dL (133 μmol/L).

               6. Any other clinically significant abnormal laboratory result as evaluated by the
                  Investigator.

               7. If no laboratory test results of the Week 22 Visit (for subjects participating in
                  the preceding ALX0061-C201 study) or the Week 10 Visit (for subjects
                  participating in the preceding ALX0061-C202 study) were available, then
                  laboratory values of tests performed between Week 22 and 24 (for study
                  ALX0061-C201) or Week 10 and 12 (for study ALX0061-C202) were taken into account
                  for the exclusion criteria a to e listed above.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Ablynx NV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator Site 1</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 2</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Burgas</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 2</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 2</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 4</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 5</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Baja</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Balatonfüred</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Bekescsaba</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Szikszó</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Székesfehérvar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Veszprém</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Culiacán</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>León</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 1</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 2</name>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Monclova</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 1</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 2</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Mérida</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 2</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1</name>
      <address>
        <city>Skopje</city>
        <country>North Macedonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 2</name>
      <address>
        <city>Skopje</city>
        <country>North Macedonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 1</name>
      <address>
        <city>Elbląg</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 2</name>
      <address>
        <city>Elbląg</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Grodzisk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Sochaczew</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 2</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Galați</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 1</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 2</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 3</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Niska Banja</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Mexico</country>
    <country>Moldova, Republic of</country>
    <country>North Macedonia</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Serbia</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Macedonia, The Former Yugoslav Republic of</country>
  </removed_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>August 6, 2015</study_first_submitted>
  <study_first_submitted_qc>August 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2015</study_first_posted>
  <results_first_submitted>April 23, 2019</results_first_submitted>
  <results_first_submitted_qc>April 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 19, 2019</results_first_posted>
  <last_update_submitted>July 19, 2019</last_update_submitted>
  <last_update_submitted_qc>July 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 10, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02518620/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02518620/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 406 subjects was enrolled at 56 sites located in Europe (48 sites, 333 subjects) and Latin America (8 sites, 73 subjects). Consent was obtained from the first subject on 13 July 2015; the last subject completed the final visit on 23 August 2018.</recruitment_details>
      <pre_assignment_details>A total of 472 subjects completed the entire treatment and assessment period of the preceding Phase IIb studies (placebo and ALX-0061 treatment arms only). Of these, 406 subjects were enrolled in this study. All screened subjects were included in the Intent-to-observe (ITO) Population. Overall, 405 subjects were included in the Safety Population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ALX-0061 150 mg q2w + MTX (C201 All Subjects)</title>
          <description>ALX-0061 150 mg s.c. q2w + methotrexate (MTX)</description>
        </group>
        <group group_id="P2">
          <title>ALX-0061 150 mg q2w (C202 All Subjects)</title>
          <description>ALX-0061 150 mg s.c. q2w</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="257"/>
                <participants group_id="P2" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor's Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy Wish</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Relocation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ALX-0061 150 mg q2w + MTX (C201 All Subjects)</title>
          <description>ALX-0061 150 mg s.c. q2w + MTX</description>
        </group>
        <group group_id="B2">
          <title>ALX-0061 150 mg q2w (C202 All Subjects)</title>
          <description>ALX-0061 150 mg s.c. q2w</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="257"/>
            <count group_id="B2" value="149"/>
            <count group_id="B3" value="406"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="339"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.7" spread="12.26"/>
                    <measurement group_id="B2" value="51.1" spread="12.01"/>
                    <measurement group_id="B3" value="51.5" spread="12.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="217"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="341"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="332"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="244"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="393"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Macedonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moldova</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Georgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bulgaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serbia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Subjects With American College of Rheumatology (ACR) 20 Response.</title>
        <description>ACR 20 response is defined as:
20% improvement in tender joint count (TJC; 68 joints) relative to Week 0 AND
20% improvement in swollen joint count (SJC; 66 joints) relative to Week 0 AND
20% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - visual analogue scale [VAS])
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI)
C-reactive protein (CRP) level
ACR20 responses were measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported.</description>
        <time_frame>At Weeks 0, 12, 48, and 104</time_frame>
        <population>ITO Population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 150 mg q2w + MTX (C201 All Subjects)</title>
            <description>ALX-0061 150 mg q2w + MTX</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q2w (C202 All Subjects)</title>
            <description>ALX-0061 150 mg q2w</description>
          </group>
          <group group_id="O3">
            <title>Total (C203 All Subjects)</title>
            <description>C203 All Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With American College of Rheumatology (ACR) 20 Response.</title>
          <description>ACR 20 response is defined as:
20% improvement in tender joint count (TJC; 68 joints) relative to Week 0 AND
20% improvement in swollen joint count (SJC; 66 joints) relative to Week 0 AND
20% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - visual analogue scale [VAS])
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by Health Assessment Questionnaire-Disability Index (HAQ-DI)
C-reactive protein (CRP) level
ACR20 responses were measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported.</description>
          <population>ITO Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="406"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="251"/>
                    <count group_id="O2" value="149"/>
                    <count group_id="O3" value="400"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="387"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221"/>
                    <measurement group_id="O2" value="130"/>
                    <measurement group_id="O3" value="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="223"/>
                    <count group_id="O2" value="134"/>
                    <count group_id="O3" value="357"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="209"/>
                    <measurement group_id="O2" value="126"/>
                    <measurement group_id="O3" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="199"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="322"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                    <measurement group_id="O2" value="117"/>
                    <measurement group_id="O3" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Subjects With ACR50 Response.</title>
        <description>ACR50 response is defined as:
50% improvement in TJC (68 joints) relative to Week 0 AND
50% improvement in SJC (66 joints) relative to Week 0 AND
50% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - VAS)
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by HAQ-DI
CRP level
ACR50 responses were measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported.</description>
        <time_frame>At Weeks 0, 12, 48, and 104</time_frame>
        <population>ITO Population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 150 mg q2w + MTX (C201 All Subjects)</title>
            <description>ALX-0061 150 mg q2w + MTX</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q2w (C202 All Subjects)</title>
            <description>ALX-0061 150 mg q2w</description>
          </group>
          <group group_id="O3">
            <title>Total (C203 All Subjects)</title>
            <description>C203 All Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With ACR50 Response.</title>
          <description>ACR50 response is defined as:
50% improvement in TJC (68 joints) relative to Week 0 AND
50% improvement in SJC (66 joints) relative to Week 0 AND
50% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - VAS)
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by HAQ-DI
CRP level
ACR50 responses were measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported.</description>
          <population>ITO Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="406"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="246"/>
                    <count group_id="O2" value="148"/>
                    <count group_id="O3" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="244"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="385"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="222"/>
                    <count group_id="O2" value="134"/>
                    <count group_id="O3" value="356"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="271"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Subjects With ACR70 Response.</title>
        <description>ACR70 response is defined as:
70% improvement in TJC (68 joints) relative to Week 0 AND
70% improvement in SJC (66 joints) relative to Week 0 AND
70% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - VAS)
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by HAQ-DI
CRP level
ACR70 responses were measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported.</description>
        <time_frame>At Weeks 0, 12, 48, and 104</time_frame>
        <population>ITO Population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 150 mg q2w + MTX (C201 All Subjects)</title>
            <description>ALX-0061 150 mg q2w + MTX</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q2w (C202 All Subjects)</title>
            <description>ALX-0061 150 mg q2w</description>
          </group>
          <group group_id="O3">
            <title>Total (C203 All Subjects)</title>
            <description>C203 All Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With ACR70 Response.</title>
          <description>ACR70 response is defined as:
70% improvement in TJC (68 joints) relative to Week 0 AND
70% improvement in SJC (66 joints) relative to Week 0 AND
70% improvement in 3 of the following 5 areas relative to Week 0:
Subject's Assessment of Pain (100 mm - VAS)
Subject's Global Assessment of Disease Activity (VASPA)
Physician's Global Assessment of Disease Activity (VASPHA)
Subject's assessment of physical function as measured by HAQ-DI
CRP level
ACR70 responses were measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported.</description>
          <population>ITO Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="406"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="147"/>
                    <count group_id="O3" value="396"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="243"/>
                    <count group_id="O2" value="141"/>
                    <count group_id="O3" value="384"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="221"/>
                    <count group_id="O2" value="133"/>
                    <count group_id="O3" value="354"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>ACR-N Index of Improvement</title>
        <description>The ACR-N Index of Improvement is defined as the minimum of the following 3 criteria:
The percent improvement from Week 0 in TJCs
The percent improvement from Week 0 in SJCs
The median percent improvement from Week 0 for the following 5 assessments:
Subject's assessment of pain (VAS)
Subject's global assessment of disease activity (VASPHA)
Physician's global assessment of disease activity (VASPHA)
Subject's assessment of physical function as measured by the HAQ-DI
CRP level
ACR-N Index of Improvement was measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported.</description>
        <time_frame>At Weeks 0, 12, 48, and 104</time_frame>
        <population>ITO Population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 150 mg q2w + MTX (C201 All Subjects)</title>
            <description>ALX-0061 150 mg q2w + MTX</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q2w (C202 All Subjects)</title>
            <description>ALX-0061 150 mg q2w</description>
          </group>
          <group group_id="O3">
            <title>Total (C203 All Subjects)</title>
            <description>C203 All Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>ACR-N Index of Improvement</title>
          <description>The ACR-N Index of Improvement is defined as the minimum of the following 3 criteria:
The percent improvement from Week 0 in TJCs
The percent improvement from Week 0 in SJCs
The median percent improvement from Week 0 for the following 5 assessments:
Subject's assessment of pain (VAS)
Subject's global assessment of disease activity (VASPHA)
Physician's global assessment of disease activity (VASPHA)
Subject's assessment of physical function as measured by the HAQ-DI
CRP level
ACR-N Index of Improvement was measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported.</description>
          <population>ITO Population</population>
          <units>percent improvement</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="406"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="256"/>
                    <count group_id="O2" value="149"/>
                    <count group_id="O3" value="405"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.77" spread="1.703"/>
                    <measurement group_id="O2" value="48.18" spread="2.171"/>
                    <measurement group_id="O3" value="52.98" spread="1.351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="252"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="394"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.51" spread="1.643"/>
                    <measurement group_id="O2" value="57.07" spread="2.181"/>
                    <measurement group_id="O3" value="59.91" spread="1.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="135"/>
                    <count group_id="O3" value="363"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.73" spread="1.691"/>
                    <measurement group_id="O2" value="66.49" spread="2.048"/>
                    <measurement group_id="O3" value="67.27" spread="1.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="328"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.83" spread="1.554"/>
                    <measurement group_id="O2" value="73.82" spread="2.171"/>
                    <measurement group_id="O3" value="74.45" spread="1.265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Subjects in Remission or With Low, Moderate or High Disease Activity Based on Disease Activity Score Using 28 Joint Counts (DAS28) Using Estimated Sedimentation Rate (ESR)</title>
        <description>DAS28(ESR) = (0.56 × √TJC28) + (0.28 × √SJC28) + (0.70 × ln[ESR]) +(0.014 × VASPA)
Remission = DAS28(ESR) &lt; 2.6
Low disease activity = 2.6 ≤ DAS28 ≤ 3.2
Moderate disease activity = 3.2 &lt; DAS28 ≤ 5.1
High disease activity = DAS28 &gt; 5.1
Disease activity based on DAS28(ESR) was measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported.</description>
        <time_frame>At Weeks 0, 12, 48, and 104</time_frame>
        <population>ITO Population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 150 mg q2w + MTX (C201 All Subjects)</title>
            <description>ALX-0061 150 mg q2w + MTX</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q2w (C202 All Subjects)</title>
            <description>ALX-0061 150 mg q2w</description>
          </group>
          <group group_id="O3">
            <title>Total (C203 All Subjects)</title>
            <description>C203 All Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects in Remission or With Low, Moderate or High Disease Activity Based on Disease Activity Score Using 28 Joint Counts (DAS28) Using Estimated Sedimentation Rate (ESR)</title>
          <description>DAS28(ESR) = (0.56 × √TJC28) + (0.28 × √SJC28) + (0.70 × ln[ESR]) +(0.014 × VASPA)
Remission = DAS28(ESR) &lt; 2.6
Low disease activity = 2.6 ≤ DAS28 ≤ 3.2
Moderate disease activity = 3.2 &lt; DAS28 ≤ 5.1
High disease activity = DAS28 &gt; 5.1
Disease activity based on DAS28(ESR) was measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported.</description>
          <population>ITO Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="406"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="253"/>
                    <count group_id="O2" value="148"/>
                    <count group_id="O3" value="401"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Remission</title>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="152"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Low Disease Activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate or High Disease Activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="248"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="386"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Remission</title>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="209"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Low Disease Activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate or High Disease Activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="220"/>
                    <count group_id="O2" value="132"/>
                    <count group_id="O3" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Remission</title>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="209"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Low Disease Activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate or High Disease Activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="121"/>
                    <count group_id="O3" value="319"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Remission</title>
                  <measurement_list>
                    <measurement group_id="O1" value="146"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="230"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Low Disease Activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate or High Disease Activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Subjects With DAS28 Using C-reactive Protein (CRP) &lt; 2.6, Low, Moderate or High Disease Activity Based on DAS28(CRP)</title>
        <description>DAS28(CRP) = (0.56 × √TJC28) + (0.28 × √SJC28) + (0.36 × ln[CRP+1]) + (0.014 × VASPA) + 0.96
DAS28(CRP) &lt; 2.6
Low disease activity = 2.6 ≤ DAS28 ≤ 3.2
Moderate disease activity = 3.2 &lt; DAS28 ≤ 5.1
High disease activity = DAS28 &gt; 5.1
Disease activity based on DAS28(CRP) was measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported.</description>
        <time_frame>At Weeks 0, 12, 48, and 104</time_frame>
        <population>ITO Population</population>
        <group_list>
          <group group_id="O1">
            <title>ALX-0061 150 mg q2w + MTX (C201 All Subjects)</title>
            <description>ALX-0061 150 mg q2w + MTX</description>
          </group>
          <group group_id="O2">
            <title>ALX-0061 150 mg q2w (C202 All Subjects)</title>
            <description>ALX-0061 150 mg q2w</description>
          </group>
          <group group_id="O3">
            <title>Total (C203 All Subjects)</title>
            <description>C203 All Subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Subjects With DAS28 Using C-reactive Protein (CRP) &lt; 2.6, Low, Moderate or High Disease Activity Based on DAS28(CRP)</title>
          <description>DAS28(CRP) = (0.56 × √TJC28) + (0.28 × √SJC28) + (0.36 × ln[CRP+1]) + (0.014 × VASPA) + 0.96
DAS28(CRP) &lt; 2.6
Low disease activity = 2.6 ≤ DAS28 ≤ 3.2
Moderate disease activity = 3.2 &lt; DAS28 ≤ 5.1
High disease activity = DAS28 &gt; 5.1
Disease activity based on DAS28(CRP) was measured at Weeks 0, 12, 24, 36, 48, 60, 72, 84, 96, and 104 and Weeks 0, 12, 48, and 104 reported.</description>
          <population>ITO Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="257"/>
                <count group_id="O2" value="149"/>
                <count group_id="O3" value="406"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="256"/>
                    <count group_id="O2" value="149"/>
                    <count group_id="O3" value="405"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>DAS(CRP) &lt; 2.6</title>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Low Disease Activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate or High Disease Activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="249"/>
                    <count group_id="O2" value="142"/>
                    <count group_id="O3" value="391"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>DAS(CRP) &lt; 2.6</title>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="223"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Low Disease Activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate or High Disease Activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="228"/>
                    <count group_id="O2" value="134"/>
                    <count group_id="O3" value="362"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>DAS(CRP) &lt; 2.6</title>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="231"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Low Disease Activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate or High Disease Activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="123"/>
                    <count group_id="O3" value="327"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>DAS(CRP) &lt; 2.6</title>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="252"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Low Disease Activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Moderate or High Disease Activity</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time of first study drug administration in study ALX0061-C203 until the subject's study completion/discontinuation date, up to a maximum of 114 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ALX-0061 150 mg q2w + MTX (C201 All Subjects)</title>
          <description>ALX-0061 150 mg s.c. q2w + MTX</description>
        </group>
        <group group_id="E2">
          <title>ALX-0061 150 mg q2w (C202 All Subjects)</title>
          <description>ALX-0061 150 mg s.c. q2w</description>
        </group>
        <group group_id="E3">
          <title>Total</title>
          <description>C203 All Subjects</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="148"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Retroperitoneal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Testicular seminoma (pure)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Transient ischemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="257"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="257"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="257"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="148"/>
                <counts group_id="E3" subjects_affected="218" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="257"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="28" subjects_affected="14" subjects_at_risk="257"/>
                <counts group_id="E2" events="23" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E3" events="51" subjects_affected="25" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="31" subjects_affected="23" subjects_at_risk="257"/>
                <counts group_id="E2" events="13" subjects_affected="12" subjects_at_risk="148"/>
                <counts group_id="E3" events="44" subjects_affected="35" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="17" subjects_at_risk="257"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="148"/>
                <counts group_id="E3" events="35" subjects_affected="28" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="257"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="148"/>
                <counts group_id="E3" events="30" subjects_affected="24" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="257"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="148"/>
                <counts group_id="E3" events="30" subjects_affected="23" subjects_at_risk="405"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="257"/>
                <counts group_id="E2" events="17" subjects_affected="10" subjects_at_risk="148"/>
                <counts group_id="E3" events="29" subjects_affected="18" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="257"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="148"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="257"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="148"/>
                <counts group_id="E3" events="18" subjects_affected="13" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="257"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="148"/>
                <counts group_id="E3" events="17" subjects_affected="17" subjects_at_risk="405"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of any results from this study will be according to the principles of the Declaration of Helsinki, in particular point 30, and will require prior review and written agreement of the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Monitor</name_or_title>
      <organization>Ablynx NV</organization>
      <phone>+32 (0)9 262 00 00</phone>
      <email>clinicaltrials@ablynx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

